Need professional-grade analysis? Visit stockanalysis.com
$1.97B
N/A
136
N/A
Kintor Pharmaceutical Ltd (9939) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD2.79, down 7.00% from the previous close.
Over the past year, 9939 has traded between a low of HKD1.09 and a high of HKD4.62. The stock has gained 87.2% over this period. It is currently 39.6% below its 52-week high.
Kintor Pharmaceutical Ltd has a market capitalization of $1.97B.
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.